StocksBiohaven Pharmaceutical Holding Co LtdBHVN

BHVN

Biohaven Pharmaceutical Holding Co Ltd

151.76 0.56 (0.37%)
Delayed Prices By NASDAQ, in USD Market Closed
Trade
S
151.51
B
152.05

Overview

Prev Close151.76
Day's Range 150.55 - 151.87
52 Week Range 78.93 - 151.87
Average Volume (3m)710.37K
1-Year Return14.25%
Beta1.1795
Market Cap10.87B
P/E Ratio
Revenue859.68M
EPS-14.8257
Dividend (Yield)0 (0%)
1 Day 1 Week 1 Month 3 Months 6 Months 1 Year 3 Years Max
Created with Highcharts 4.2.7 /Highstock 4.2.711/04/202227/06/202206/09/202290.00100.00110.00120.00130.00140.00150.00160.00
Chart times in UTC
Industry Pharmaceuticals Major
CEO Vladimir Coric, MD
Employees 928

FINANCIAL SUMMARY

For the fiscal year ended 31/12/2021: Biohaven Pharmaceutical Holding Co Ltd's revenues increased by 626.91% and amounted to 462.51M. Net income decreased by 10.38% to -848.40M. Net assets decreased by 105.61% to -683.01M and EPS decreased from -13.06 to -13.09.
BHVN's Investor Relations
Income StatementBalance SheetCash Flow Statement
Quarterly
Gross Margin
85.63%
Net Profit Margin
-277.64%
Operating Margin
-74.44%
Return On Investment
-164.14%
09/21
12/21
03/22
06/22
Total Revenue
135.74M
190.01M
318.85M
215.08M
Gross Profit
110.23M
154.06M
292.51M
179.34M
Operating Income
-139.95M
-156.53M
-53.83M
-289.6M
Net Income
-172.33M
-199.58M
-116.9M
-441.89M